Manufacturer

AstraZeneca AB

Country

SWEDEN

Certificates

FDA

Document

1.2 MB

Registration Date	18 Jul 2016
Share

BRILINTA

(0)

Medicine Pharmaceuticals Product Number : 0186-0777-18

Platelet Aggregation Inhibitors

Drug Information

Generic

Ticagrelor

NDC Code

0186-0777-18

Drug Class

ADP-Induced Aggregation Inhibitor

Therapeutic Class

Platelet aggregation inhibitors

Dosage form

tablet

Therapeutic Area

1.acute coronary syndromes (ACS)

Indication

BRILINTA is indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS. (reduction of thrombotic events in patients with acute coronary syndrome).

Benefit

Antiplatelet drug ticagrelor (Brilinta®) works faster and is more effective in blocking platelet activity in low-risk patients with acute coronary syndrome (ACS), reduction of thrombotic events in patients with acute coronary syndrome.